We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1B
AUM Growth
+$73.5M
Cap. Flow
-$38M
Cap. Flow %
-3.79%
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$17.5M
2
MDT icon
Medtronic
MDT
+$16.5M
3
TMO icon
Thermo Fisher Scientific
TMO
+$16M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$11.2M
5
RPRX icon
Royalty Pharma
RPRX
+$7.69M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$24.6M
2
LLY icon
Eli Lilly
LLY
+$12.8M
3
CVS icon
CVS Health
CVS
+$11.6M
4
ELV icon
Elevance Health
ELV
+$11.6M
5
MCK icon
McKesson
MCK
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
51
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.45M 0.64%
90,000
-5,000
-5% -$288K
AXSM icon
52
Axsome Therapeutics
AXSM
$11.4B
$6.3M 0.63%
79,100
+39,000
+97% +$2.61M
IMVT icon
53
Immunovant
IMVT
$8.24B
$6.15M 0.61%
146,061
-20,000
-12% -$736K
ELV icon
54
Elevance Health
ELV
$86.2B
$6.13M 0.61%
13,000
-25,000
-66% -$11.6M
APLS
55
DELISTED
Apellis Pharmaceuticals
APLS
$6.01M 0.6%
100,400
-114,600
-53% -$5.81M
IMCR icon
56
Immunocore
IMCR
$1.73B
$5.76M 0.58%
84,278
-5,000
-6% -$260K
ARVN icon
57
Arvinas
ARVN
$588M
$5.53M 0.55%
134,270
+49,270
+58% +$1.15M
BBIO icon
58
BridgeBio Pharma
BBIO
$16.6B
$5.45M 0.54%
135,000
– –
MDGL icon
59
Madrigal Pharmaceuticals
MDGL
$11.9B
$5.21M 0.52%
+22,500
New +$3.94M
XNCR icon
60
Xencor
XNCR
$1.6B
$4.78M 0.48%
225,000
– –
RLAY icon
61
Relay Therapeutics
RLAY
$4.37B
$4.29M 0.43%
390,000
+200,000
+105% +$1.69M
RVNC
62
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.18M 0.42%
475,872
+114,193
+32% +$936K
PODD icon
63
Insulet
PODD
$9.91B
$4.12M 0.41%
+19,000
New +$3.26M
INSP icon
64
Inspire Medical Systems
INSP
$1.73B
$3.66M 0.37%
18,000
+11,000
+157% +$1.78M
LH icon
65
Labcorp
LH
$26.1B
$3.41M 0.34%
+15,000
New +$3.15M
VKTX icon
66
Viking Therapeutics
VKTX
$4.02B
$3.35M 0.33%
180,000
– –
WST icon
67
West Pharmaceutical
WST
$24.8B
$3.17M 0.32%
9,000
– –
HCAT icon
68
Health Catalyst
HCAT
$129M
$2.78M 0.28%
300,000
-20,000
-6% -$163K
TGTX icon
69
TG Therapeutics
TGTX
$7.52B
$2.73M 0.27%
160,000
– –
LNTH icon
70
Lantheus
LNTH
$6.59B
$2.48M 0.25%
40,000
-128,000
-76% -$8.67M
NVCR icon
71
NovoCure
NVCR
$2.02B
$2.39M 0.24%
+160,000
New +$2.14M
EPIX
72
DELISTED
ESSA Pharma
EPIX
$2.35M 0.24%
356,500
– –
PLRX icon
73
Pliant Therapeutics
PLRX
$64.4M
$2.04M 0.2%
+112,741
New +$1.71M
INMB icon
74
INmune Bio
INMB
$58.8M
$2.01M 0.2%
178,284
– –
RGEN icon
75
Repligen
RGEN
$9.21B
$1.8M 0.18%
+10,000
New +$1.56M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rhenman & Partners Asset Management held 100 positions worth $1B, up 7.9% from $928M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $38M in Q4 2023, closing 15 positions and reducing 32 holdings. Its most notable exit was Becton Dickinson, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pfizer worth $16.7M.

  • Rhenman & Partners Asset Management's largest Q4 2023 buy was Pfizer: 580,000 shares worth $16.7M.
  • Rhenman & Partners Asset Management added most to Medtronic in Q4 2023, an estimated $16.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2023 reduction was Eli Lilly, cutting an estimated $12.8M.
  • Rhenman & Partners Asset Management fully exited Becton Dickinson in Q4 2023, selling an estimated $24.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1B portfolio in Q4 2023.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 15 in Q4 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 7.9% quarter-over-quarter to $1B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.